avigena

OMNIINSIGHT™ BREAST CANCER PROGRAM

*A comprehensive, MENA-focused approach integrating **polygenic risk scores (PRS)**, **monogenic variant testing, clinical factors, and lifestyle** to deliver individualized breast cancer prevention strategies.*

WHY PRS MATTERS

- Traditional genetic testing alone is **not enough.**
- PRS detects hidden high risk—**even in women with no BRCA or other mutations.**
- **PRS also modifies risk for mutation carriers:** two women with the same mutation can have very different levels of risk.
- Uses a clinically validated multi-ancestry PRS, calibrated for diverse populations including the MENA region.

PERSONALIZED PREVENTION

Results are translated into **a clinically actionable care plan** aligned with best-practice guidelines, enabling personalized recommendations for **screening, lifestyle modification, medical interventions, and genetic counseling.**



avigena

MONOGENIC RISK COVERAGE

Monogenic Risk Coverage Identifies high-impact pathogenic variants across **NCCN**-recommended breast cancer genes, including: **BRCA1, BRCA2, ATM, BARD1, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53.**

POWERED BY BLENDED GENOME EXOME

The innovative genomic technology is developed in collaboration **with Broad Clinical Labs at Harvard and MIT**, the program combines **95.5× Whole- Exome Sequencing (WES)** with **genome-wide lcWGS** to detect both rare mutations and polygenic risk with high precision.

Testing is performed through **CAP/CLIA-accredited laboratories,** with analytics support from **Allelica**, (MGB/LMM), and regional collaboration with **Novo Genomics.**
Equipped with most precise risk assessment available.

SCAN ME

Get started today
info@avigena.com
+1 617 412 5580